An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2007-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMCL.2007.01.008PMID 17258456
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.

  2005cited by this paper
• Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.

  2005cited by this paper
• An efficient sequence for the preparation of small secondary amine hydrochloride salts for focused library generation without need for distillation or chromatographic purification.

  2004cited by this paper
• 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy.

  2003cited by this paper
• International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands

  2003cited by this paper
• Chapter 2. Neuropeptide receptor antagonists for CNS disorders

  2003cited by this paper
• Cushing’s syndrome: drug targets and therapeutic options

  2002cited by this paper
• Nonpeptide corticotropin releasing hormone type 1 receptor antagonists as medications and imaging agents

  2002cited by this paper
• Are CRF receptor antagonists potential antidepressants?

  2001cited by this paper
• The CRF Receptor Structure, Function and Potential for Therapeutic Intervention.

  2001cited by this paper
• Novel approaches to the treatment of depression by modulating the hypothalamic – pituitary – adrenal axis

  2001cited by this paper
• Corticotropin releasing hormone: therapeutic implications and medicinal chemistry developments.

  2000cited by this paper
• Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.

  2000cited by this paper
• Synthesis and study of the hypotensive and antiarrhythmic activity of 2,9-disubstituted 3-alkoxycarbonylmidazo [1,2-a]benzimidazoles

  1999cited by this paper
• Behavioural and pharmacological characterisation of the canopy stretched attend posture test as a model of anxiety in mice and rats

  1997cited by this paper
• Functional corticotropin-releasing factor receptors in human neuroblastoma cells.

  1996cited by this paper
• Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication.

  1995cited by this paper
• Improved Preparation of 2-Nitrodiphenylamines

  1980cited by this paper

• Design, Synthesis, Structural Optimization, SAR, in silico Prediction of Physicochemical Properties and Pharmacological Evaluation of Novel & Potent Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists.

  2021cites this paper
• Synthesis of 2-imino and 2-hydrazono thiazolo[4,5-d]pyrimidines as corticotropin releasing factor (CRF) antagonists.

  2017cites this paper
• Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.

  2017cites this paper
• Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.

  2012cites this paper
• 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.

  2011cites this paper
• Progress in corticotropin-releasing factor-1 antagonist development.

  2010cites this paper
• CRF 1 antagonists in animal models of anxiety , depression and addictive disorders

  2010cites this paper
• Syntheses of aza and fluorine-substituted 3-(piperidin-4-yl)-4,5-dihydro-1H-benzo[d][1,3]diazepin-2(3H)-ones

  2009cites this paper
• Chapter 1 Recent Advances in Corticotropin-Releasing Factor Receptor Antagonists

  2008cites this paper
• An Orally Active Corticotropin Releasing Factor 1 Receptor Antagonist from 8‐Aryl‐1,3a,7,8‐tetraaza‐cyclopenta[a]indenes.

  2007cites this paper